Goldline Pharmaceutical Limited is set to secure ₹12 crore in capital via its upcoming public offering. It will issue a total of 27,00,000 shares. The subscription window for potential investors is scheduled to open on May 8, 2026, and will remain active for bidding until the May 12, 2026 deadline. The business intends to finalise the distribution of shares to successful bidders by May 15, 2026. Shares from the issue are scheduled to be listed and traded on BSE SME on May 19, 2026.
Each application lot under this IPO includes 3,000 shares. The share price for this issuance has been fixed within a range of ₹41 to ₹43. To participate, retail category investors must subscribe to a minimum of two lots, necessitating an upfront commitment of ₹2,58,000. The outlay for the HNI category starts at three lots, requiring a minimum investment of ₹3,87,000.
Goldline Pharmaceutical IPO Details
Below is a snapshot of the important IPO-related details.
| Particulars | Details |
| Bidding Opens | May 12, 2026 |
| Bidding Closes | May 14, 2026 |
| Issue Type | Book Building Issue |
| Face Value | ₹10 per share |
| Price Band | ₹41 to ₹43 |
| Listing at | BSE SME |
| Lot Size | 3,000 Shares |
| Reserved for Market Maker | 1,38,000 shares |
| Offer for Sale(OFS) | – |
| Fresh Issue | 25, 62,000 shares (₹11 Crore) |
| Total Issue | 27,00,000 shares (₹12 Crore) |
| Minimum Investment | ₹2,58,000 (6,000 shares) |
Goldline Pharmaceutical IPO Timeline
You can find the preliminary timeline and key milestones for this public offering in the following chart.
| Particulars | Details |
| Bidding Opens | May 12, 2026 |
| Bidding Closes | May 14, 2026 |
| Allotment Expected | May 15, 2026 |
| Refunds Start On | May 18, 2026 |
| Share Credit to Demat | May 18, 2026 |
| Listing Scheduled | May 19, 2026 |
| Cut-off for UPI Mandate | 5:00 PM on May 14, 2026 |
Goldline Pharmaceutical Key Performance Indicators (KPI)
Given in this section are the company’s important KPI for IPO to figure across recent years.
| KPIs | FY25 | FY24 | FY23 |
| ROE (%) | 35.83 | 31.31 | 0.90 |
| ROCE (%) | 38.45 | 32.40 | 19.43 |
| Debt Equity (times) | 1.50 | 2.14 | 3.09 |
| RoNW (%) | 27.37 | 22.94 | 4.36 |
| PAT Margin (%) | 10.09 | 7.66 | 1.29 |
| EBITDA Margin (%) | 20.78 | 18.25 | 11.06 |
| Price Book Value | – | – | – |
Goldline Pharmaceutical Financials
The details in this table outlines Goldline Pharma’s financial figures:
| Particulars (in ₹ lakh) | FY25 | FY24 | FY23 |
| Total Assets | 2,628.01 | 2293.46 | 1938.82 |
| Revenue (from Operations) | 2,805.57 | 2,356.60 | 1984.84 |
| Profit (After Tax) | 283.22 | 180.40 | 25.66 |
Goldline Pharmaceutical IPO Subscription Status
As the Goldline Pharmaceutical IPO is yet to open, subscription numbers have not been disclosed. These figures will be updated after bidding commences on May 12, 2026.
The window for submitting subscription forms remains open from 10:00 AM until 5:00 PM during the bidding days. QIBs and non-institutional investors must submit applications by 4:00 PM on the closing date.
Goldline Pharmaceutical IPO Grey Market Premium
Goldline Pharmaceutical IPO has a GMP of Rs 0 at present, indicating mixed market interest. As per this, it implies the shares may debut near the ₹43 offer price, indicating that investors might not see significant premium gains upon listing.
| GMP Date | GMP | Est. Listing Price | Est. Profit* | Last Updated |
|---|---|---|---|---|
| 11-05-2026 | ₹17 ▲ | ₹60 (39.53%) | ₹51,000 | 11-May-2026 20:33 |
| 10-05-2026 | ₹16 ▲ | ₹59 (37.21%) | ₹48,000 | 10-May-2026 23:32 |
| 09-05-2026 | ₹15 ▲ | ₹58 (34.88%) | ₹45,000 | 9-May-2026 23:33 |
| 08-05-2026 | ₹8 ▲ | ₹51 (18.60%) | ₹24,000 | 8-May-2026 23:35 |
Note: GMP data is extracted from unofficial sources and are provided solely for reference. They do not indicate guaranteed listing performance.
Goldline Pharmaceutical IPO Reservation
The table below shows the share allocation reserved for different investor categories in the issue.
| Investor Category | Reservation |
| Market Maker Shares | 1,38,000 |
| QIB Shares | Not more than 49.65% of Net Issue |
| NII (HNI) Shares | Not less than 15.22% of Net Issue |
| Retail Shares | Not less than 35.13% of Net Issue |
| Total Shares | 27,00,000 |
Goldline Pharmaceutical IPO Lot Size
The table below presents the minimum and maximum application details for retail and HNI investors applying to the Goldline Pharmaceutical IPO.
| Application | Lots | Shares | Amount |
| Individual investors (Retail) (Min) | 2 | 6,000 | ₹2,58,000 |
| Individual investors (Retail) (Max) | 2 | 6,000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 9,000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 21,000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 24,000 | ₹10,32,000 |
Goldline Pharmaceutical IPO Anchor Investors
The anchor investor segment details for the issue are outlined below.
| Particulars | Details |
| Anchor Bidding Opens | May 11, 2026 |
| Shares Offered | Up to 7,32,000 Equity Shares |
| Portion Size | A maximum of 60% of the QIB criteria |
| 50% Shares Lock-in (30 Days) | June 10, 2026 |
| Remaining shares Lock-in (90 Days) | August 9, 2026 |
Goldline Pharmaceutical IPO Prospectus
The following documents provide detailed information related to the IPO and the company’s business operations.
| Draft Red Herring Prospectus (DRHP) | |
| Red Herring Prospectus (RHP) | |
| Anchor Investors | – |
| Final Prospectus | Not Disclosed Yet |
About Goldline Pharmaceuticals
Initially established as a private entity on August 2, 2004, Goldline Pharmaceutical Limited was formed in accordance with the Companies Act, 1956. The business subsequently transitioned into a public limited company during September 2013. The company is promoted by Amol Laxmikant Mujumdar, who brings 25 years of experience in pharmaceutical marketing, and Swapan Premprakash Khandelwal, who brings 30 years of experience in supply chain management. Both promoters hold 39.85% of the pre-issue equity share capital each.
Currently, the firm distributes a diverse range of medicinal products under its proprietary ‘Goldline’ trademark, categorised into five specific therapeutic areas. It is important to note that the company does not maintain its own production plants, opting instead for an outsourced model.
Instead, the company works with 15 third-party contract manufacturers and distributes through 8 distributors, operating through a fully asset-light model. The main five product segments include:
- Goldline Pharma: 42 products covering Physicians, Orthopaedics, ENT, Gastroenterology, Neurology, and Urology
- Goldline Cardinal: 54 products for cardiology, diabetology, and endocrinology
- Goldline Aayushman: 18 products for gynaecology, paediatrics, and neonatology
- Goldline InLife: 22 products for critical care, ICU, injectable, and hospital settings
- Goldline Wellness: 10 products focused on supportive and adjunct oncology care
| Lead Manager | Cumulative Capital |
| IPO Registrar | Bigshare Services Private Limited |
Goldline Pharmaceutical IPO Objectives
The IPO proceeds are proposed to be allocated towards the following business requirements.
| Particulars | Amount (in ₹ Cr) |
| A portion of the proceeds will be used for the full or partial settlement of specific existing debts incurred by the company | 8.35 |
| General Corporate Purposes | – |
| Total | 8.35 |
Strengths of Goldline Pharmaceuticals
Goldline Pharmaceutical’s business model and financial growth are supported by the following key factors:
- Asset-Light Model: All manufacturing is outsourced to WHO-GMP and ISO-certified third-party manufacturers, keeping capital expenditure minimal and operations scalable without heavy infrastructure investment.
- Diversified Portfolio Across 146 Products: Five clearly defined segments covering general medicine, cardiology, paediatrics, critical care, and oncology support reduce revenue dependence on any single therapeutic area.
- Experienced Promoter Leadership: Both promoters bring over two decades of pharmaceutical marketing and supply chain experience, providing strategic direction and industry relationships.
- Growing Revenue Pattern: Revenue from operations grew from Rs 1,984.84 lakh in FY23 to Rs 2,805.57 lakh in FY25, with PAT expanding sharply from Rs 25.66 lakh to Rs 283.22 lakh in the same period, reflecting improving operational leverage.
- Conservative Leverage: The debt-to-equity ratio has declined sharply from 3.09 times in FY23 to 0.90 times in FY25, indicating meaningful debt reduction.
Risks of Goldline Pharmaceuticals
It is easential to carefully evaluate the potential vulnerabilities listed below before making a decision.
- Complete Reliance on Third-Party Manufacturers: The organisation operates without its own production plants, instead relying entirely on external partners for fabrication. Any failure by contract manufacturers to meet quality, regulatory, or delivery requirements could directly disrupt operations and revenue.
- Concentrated Distribution: Financial stability is tied to a small group of eight distributors who contribute the majority of the company’s income. Loss of any key distributor relationship could materially impact financial results.
- Historical Compliance Lapses: Past operations have seen occasional friction with administrative deadlines, including late GST submissions and delayed e-form filings with the RoC (Registrar of Companies). While no major regulatory action has been imposed to date, future penalties remain a risk.
- Promoter Group Conflict of Interest: Potential conflicts of interest exist with several promoter-led organisations specifically Nucleage Pharma Solutions, Nucleage Lifescience, and Numerius Healthcare, which operate in the same market space and may compete with the company.
- Negative Cash Flows in Past Years: The company has reported negative cash flows in certain past periods. Sustained negative cash flows could constrain growth and operational capacity.
- Geographic Concentration: Operations are primarily concentrated in Maharashtra, with limited diversification across other Indian states, making the company vulnerable to regional disruptions.
Goldline Pharmaceuticals IPO Review
Goldline Pharmaceutical is a moderate to high-risk SME offering. Its strengths lie in a lean operating model and an expanding product range. Its weaknesses lie in governance, concentration risks, and compliance history. The neutral GMP of Rs 0 reflects measured market sentiment. Investors with a high risk appetite and strong understanding of SME pharmaceutical companies may consider evaluating this issue carefully before applying.
Other Recent IPO List
Discover more IPOs that are recently launched or expected to open soon.
Goldline Pharmaceuticals IPO FAQs
Goldline Pharmaceutical IPO is an SME book-building issue of 27,00,000 equity shares worth approximately ₹12 crore, proposed to be listed on the BSE SME platform on May 19, 2026.
Apply through your broker via ASBA using net banking or UPI by selecting the IPO during the subscription period of May 12 to May 14, 2026.
The IPO is conservatively priced at 4.1x to 4.3x P/E with a growing revenue base and asset-light model. However, complete dependence on third-party manufacturers, promoter group conflicts, and a neutral GMP make it a moderate to high-risk offering requiring careful evaluation.
The lot size is 3,000 shares. The minimum application for retail investors is 2 lots, valued at ₹2,58,000 at the highest price band.
The basis of allotment may be finalised by May 15, 2026.
Shares are likely to start trading on BSE SME from May 19, 2026.
The current GMP is Rs 0, indicating neutral sentiment and an expected listing near the issue price of ₹43 with no immediate listing gains anticipated.
